Lexapro®'s Efficacy After Dose Escalation in Remission Study (LEADERS)
A Double-blinded 6-week Prospective Study to Evaluate the Remission Rate According to Dose of Escitalopram (Lexapro®) in Patients With Major Depressive Disorder: a Preliminary Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of
- Seoul National University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age: 18 ~ 65
- Patient with major depressive disorder according to DSM-IV criteria
- Patient have signed on the informed consent, and well understood the objective and procedure of this study.
- MADRS total score ≥ 18
- Competent patient who is manage to answer the questionnaires.
- In case of female at child-bearing age, consent to use appropriate contraceptive methods(oral pill, contraceptive injection, intrauterine device, double barrier method and contraceptive patch) during entire duration of this study.
Exclusion Criteria:
- In previous depressive episodes, no efficacy although more than one antidepressant treatment
- Allergy or hypersensitivity to escitalopram
- Diagnosed to schizophrenia or bipolar disorder or schizoaffective disorder (DSM-IV)
- MADRS 10 score ≥ 5, or patient who is supposed to be impossible to participate to this study due to clinical risk of suicide or aggressive behavior based on clinician's opinion
- Pregnant or breast-feeding female patient
- Significant biochemical or hematological abnormality or abnormal finding of urinalysis, based on clinician's opinion
- Significant severe medical condition
- Patients who take antipsychotics or mood stabilizer or other psychiatric drugs excluding benzodiazepines or beta blockers or hypnotics
- History of participating to other investigational drug trial within 1month prior to screening
- Investigator or employee at clinical trial center, personnel related to investigator or trial center on this or other study, or family of employee or investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Escitalopram, 20mg, placebo
escitalopram 20mg + placebo (same taste, appearance, texture of escitalopram 10mg)
|
escitalopram 20mg and 30mg p.o. daily, 6 weeks
Other Names:
escitalopram 10mg p.o. for 1 week, and escitalopram 20mg p.o. for 3 weeks before randomized to placebo and experimental groups
Other Names:
|
|
Experimental: Escitalopram 20mg, escitalopram 10mg
Escitalopram 20mg + Escitalopram 10mg
|
escitalopram 20mg and 30mg p.o. daily, 6 weeks
Other Names:
escitalopram 10mg p.o. for 1 week, and escitalopram 20mg p.o. for 3 weeks before randomized to placebo and experimental groups
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Montgomery-Åsberg Depression Rating Scale (MADRS)
Time Frame: 6 weeks
|
6 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Hamilton Depression Rating Scale-17 items (HAM-D)
Time Frame: 6 weeks
|
6 weeks
|
|
Hamilton Anxiety Rating Scale (HAM-A)
Time Frame: 6 weeks
|
6 weeks
|
|
Clinical Global Impression-severity (CGI-S)
Time Frame: 6 weeks
|
6 weeks
|
|
Clinical Global Impression-Improvement (CGI-I)
Time Frame: 6 weeks
|
6 weeks
|
|
Beck's Depression Inventory(BDI)
Time Frame: 6 weeks
|
6 weeks
|
|
WHO Quality Of Life scale Abbreviated Version(WHOQOL-BREF)
Time Frame: 6 weeks
|
6 weeks
|
|
Clinically Useful Depression Outcome Scale (CUDOS)
Time Frame: 6 weeks
|
6 weeks
|
|
Short From-36 Health survey (SF-36 Health survey)
Time Frame: 6 weeks
|
6 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Mood Disorders
- Depression
- Depressive Disorder
- Depressive Disorder, Major
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Parasympatholytics
- Autonomic Agents
- Peripheral Nervous System Agents
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Antidepressive Agents, Second-Generation
- Antiparkinson Agents
- Anti-Dyskinesia Agents
- Citalopram
- Dexetimide
Other Study ID Numbers
Other Study ID Numbers
- AYM-LEADERS
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.